Two Products to be Discontinued

Takeda announced that it will globally discontinue two of its hemophilia A treatments: Hemofil M, a plasma-derived therapy, and Recombinate, the first genetically-created hemophilia therapy, launched in 1992. Takeda intends to supply both products to patients already receiving them until inventory is depleted or expired, which is estimated to be mid-2026. Read more here.